WELL Health Technologies reported strong Q3 results with revenue up 12% year-over-year and Adjusted EBITDA exceeding consensus estimates. This positive performance, coupled with reaffirmed guidance and a potential U.S. asset sale, suggests continued growth and potential for increased shareholder value.
WELL Health Technologies announced robust third-quarter results, with revenue increasing 12% year-over-year and Adjusted EBITDA surpassing analyst expectations. This strong performance led Haywood Securities to maintain a 'Buy' rating and an $8.00 price target, indicating continued confidence in the company's trajectory. The potential sale of U.S. assets is a significant opportunity, as it could unlock further shareholder value and streamline operations. Management's reaffirmed fiscal 2026 Adjusted EBITDA guidance and updated revenue outlook provide a clear positive signal for long-term investors, while the immediate positive Q3 results offer short-term trading opportunities.